Million Dollar Acquisition of CardioComm Solutions Shares. MD Primer Inc. Exercises its Warrants
February 13, 2012 14:05 ET
Million Dollar Acquisition of CardioComm Solutions Shares. MD Primer Inc. Exercises its Warrants
TORONTO, ONTARIO--(Marketwire - Feb. 13, 2012) - Dr. Anatoly Langer, the Chairman of CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions"), announced that MD Primer Inc. ("MDP", which is under Dr. Langer's control and direction) has acquired 10,000,000 common shares of CardioComm Solutions through the exercise of 10,000,000 common share purchase warrants at a price of $0.10 per share. The shares involved represent approximately 11.3% of the issued and outstanding common shares of CardioComm Solutions.
"MD Primer has long been a CardioComm Solutions supporter and believer in CardioComm Solutions' technologies and staff. Through a difficult three year period, MD Primer has stood largely alone in ensuring CardioComm Solutions had the needed cash flow to meet its aggressive and game changing objectives. With the recent FDA clearance of the HeartCheck™ Pen, the newest technology to come out of this innovative company, and the continued market response, MD Primer can now take the opportunity to recover on its initial investments. MD Primer will remain a strong supporter as a major shareholder while CardioComm Solutions continues implementing its business plan efficiently and effectively," said Dr. Anatoly Langer, owner of MD Primer Inc. and Chairman of the CardioComm Solutions board of directors.
Dr. Anatoly Langer, together with his personal holdings and those of MDP, owns or has control and direction over an aggregate of 51,530,581 CardioComm Solutions common shares, representing approximately 58.37% of the issued and outstanding common shares.
To review the report associated with this news release, please go to CardioComm's profile on SEDAR at [ www.sedar.com ] or contact CardioComm at 1.800.725.6585, ext. 264.
Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of MD Primer and certain of the plans and objectives of MD Primer with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Dr. Langer has previously purchased shares from CardioComm Solutions for investment purposes, and in the future may further purchase, hold, vote, trade, dispose or otherwise deal in the common shares of CardioComm Solutions in such manner as he deems advisable to benefit from changes in market prices of such common shares, changes in the operations of CardioComm Solutions, its business strategy or prospects, or from a sale or merger of CardioComm Solutions.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.